ACI-35 is under clinical development by AC Immune and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect ACI-35’s likelihood of approval (LoA) and phase transition for Alzheimer’s Disease took place on 18 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ACI-35 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
ACI-35 (anti-tau vaccine) is under development for the treatment of Alzheimer's disease. It is administered through parenteral route. It is a liposomal vaccine and is based on SupraAntigen technology platform. The drug candidate targets microtubule-associated protein tau.
AC Immune overview
AC Immune is a clinical-stage biopharmaceutical company that discovers, designs and develops proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms: SupraAntigen and Morphomer. Its technology platforms help the company to design, discover and develop antibodies, small molecules and vaccines. AC Immune’s product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company’s lead product candidate, crenezumab, is a monoclonal antibody that targets abeta in cognitive healthy individuals who are at risk of developing familial Alzheimer’s Disease (fAD). AC Immune is headquartered in Lausanne, Switzerland.
Quick View ACI-35 LOA Data
|Highest Development Stage|